Cardio Diagnostics Holdings Business Summary

Cardio Diagnostics Holdings, Inc. (CDIO) is an artificial intelligence-powered precision medicine company specializing in the commercialization of epigenetic-genetic clinical tests for cardiovascular disease. The company generates revenue primarily through transaction-based sales of its flagship diagnostic products, Epi+Gen CHD™ and PrecisionCHD™, which are reimbursed by the Centers for Medicare and Medicaid Services (CMS) at a final gapfill rate of $854 per test. Its business model is bifurcated into clinical diagnostics and population health intelligence, the latter driven by its HeartRisk™ platform, which provides data-driven risk assessments for employers, payers, and correctional facilities. CDIO also operates a biopharma segment, CardioInnovate360™, offering research-use-only (RUO) solutions for drug discovery and validation. While the company competes broadly with biotechnology peers like 60 Degrees Pharmaceuticals and Alpha Tau Medical, its most direct functional competitors are AI-driven cardiac imaging firms such as Cleerly and HeartFlow; however, CDIO maintains a unique market position as the only commercial provider leveraging blood-based epigenetic biomarkers rather than imaging-centric modalities. The company was co-founded by CEO Meeshanthini (Meesha) V. Dogan, PhD, and Chief Medical Officer Robert (Rob) Philibert, MD, PhD, both of whom possess extensive pedigrees in genomics and artificial intelligence. Dr. Dogan’s background bridges pioneering work in DNA methylation with commercial scaling, while Dr. Philibert is a widely published physician-scientist specializing in the molecular basis of complex diseases. The executive team is rounded out by Chief Technology Officer Timur Dogan, PhD, and Chief Financial Officer Elisa Luqman, JD, MBA. CDIO is governed by a board led by Non-Executive Chairman Warren Hosseinion, MD, and includes notable directors such as Paul F. Burton of 2Flo Ventures. Despite its micro-cap status, the company has attracted institutional interest from high-profile investors including Millennium Management, Citadel Advisors, and Jane Street Group, signaling confidence in its proprietary Integrated Genetic-Epigenetic Engine.